Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Jun 2 · above the Ichimoku cloud · RSI 51 · MACD below its signal
None of the 29 investors followed here reported a position in ADAPY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ADAPY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.7 | -28.6 | 0.0 | -50.0 | -40.0 | 516.7 | -13.5 | -28.1 | 65.2 | -23.7 | +11.5% | ||
| 2025 | 9.5 | -8.5 | -63.5 | 40.6 | 5.8 | -18.1 | -66.7 | -26.2 | 120.3 | -61.5 | -24.0 | -31.6 | −95.2% |
| 2024 | 21.1 | 63.5 | 0.6 | -24.7 | -5.0 | -13.7 | 36.4 | -4.5 | -25.2 | -23.6 | -0.7 | -25.2 | −32.0% |
| 2023 | 28.1 | -5.3 | -38.4 | 30.3 | -28.2 | -9.3 | 1.8 | -17.2 | 0.0 | -30.6 | -7.6 | 58.6 | −45.7% |
| 2022 | -22.1 | -11.0 | -20.8 | -16.5 | -16.3 | 18.1 | 8.8 | 7.0 | -45.7 | 32.1 | 52.8 | -32.7 | −61.1% |
| 2021 | 1.3 | 1.5 | -4.2 | 6.6 | -11.1 | -15.3 | -16.2 | 44.8 | 0.0 | -1.9 | -18.1 | -9.6 | −30.4% |
| 2020 | 225.0 | -7.2 | -24.9 | 23.5 | 229.5 | -9.6 | -6.6 | -7.0 | -8.3 | -43.5 | 11.1 | 7.6 | +349.2% |
| 2019 | -15.3 | -9.9 | -2.1 | 11.6 | -27.9 | 16.2 | -18.2 | -51.1 | -6.2 | -41.7 | 33.0 | 2.6 | −79.1% |
| 2018 | 29.2 | -11.6 | 47.2 | 13.2 | 4.2 | -10.3 | -17.6 | 17.8 | 17.7 | -54.3 | -0.6 | -6.7 | −13.9% |
| 2017 | 6.4 | -6.5 | 36.7 | -2.2 | -2.0 | -15.0 | 16.9 | 33.3 | 17.0 | -4.2 | 5.5 | -19.3 | +64.9% |
| 2016 | -41.4 | 1.7 | 13.1 | 19.2 | 6.2 | -20.8 | -0.4 | -17.5 | 5.2 | -38.3 | -4.1 | -2.9 | −66.4% |
| 2015 | 18.8 | -17.9 | -27.2 | 9.2 | -10.9 | -15.2 | 33.4 | −21.8% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2025 | Bertrand William C JrChief Operating Officer | Sale at price 0.07 per share. | 207K | $14.26K |
| Aug 17, 2025 | Behbahani AliDirector | Sale at price 0.06 - 0.07 per share. | 19.50M | $1.31M |
| Jul 29, 2025 | Ecor1 Capital, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.10 - 0.11 per share. | 64.05M | $6.89M |
| Jan 16, 2025 | Rawcliffe AdrianChief Executive Officer | Sale at price 0.58 per share. | 30.6K | $17.77K |
| Jan 16, 2025 | Lunger JohnOfficer | Sale at price 0.58 per share. | 5.6K | $3.24K |
| Jan 16, 2025 | Norry ElliotOfficer | Sale at price 0.58 per share. | 5.6K | $3.24K |
| Jan 16, 2025 | Bertrand William C JrChief Operating Officer | Sale at price 0.58 per share. | 5.6K | $3.24K |
| Jan 14, 2025 | Rawcliffe AdrianChief Executive Officer | Sale at price 0.57 - 0.59 per share. | 59.6K | $34.64K |
| Jan 14, 2025 | Lunger JohnOfficer | Sale at price 0.57 - 0.59 per share. | 19.5K | $11.36K |
| Jan 14, 2025 | Norry ElliotOfficer | Sale at price 0.57 - 0.59 per share. | 22.2K | $12.92K |
| Jan 14, 2025 | Piccina CintiaOfficer | Sale at price 0.57 per share. | 13K | $7.47K |
| Jan 14, 2025 | Bertrand William C JrChief Operating Officer | Sale at price 0.57 - 0.59 per share. | 19.5K | $11.36K |
No analyst coverage for this instrument.
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.